These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12940439)

  • 41. [Epidemiology of the two types of gastric adenocarcinoma in Iceland according to the Laurén histological classification 1990-2009].
    Olafsdottir HS; Alexiusdottir KK; Lund SH; Jonasson JG; Jonsson T; Skuladottir H
    Laeknabladid; 2016 Mar; 102(3):125-30. PubMed ID: 26985590
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical significance of expression of proliferating cell nuclear antigen and E-cadherin in gastric carcinoma.
    Hu L; Li HL; Li WF; Chen JM; Yang JT; Gu JJ; Xin L
    World J Gastroenterol; 2017 May; 23(20):3721-3729. PubMed ID: 28611525
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum endostatin levels in gastric cancer patients: correlation with clinicopathological parameters.
    Koç M; Göçmen E; Kiliç M; Ozbay M; Oktem M; Tez M
    Hepatogastroenterology; 2006; 53(70):616-8. PubMed ID: 16995474
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.
    Park DJ; Yoon C; Thomas N; Ku GY; Janjigian YY; Kelsen DP; Ilson DH; Goodman KA; Tang LH; Strong VE; Coit DG; Yoon SS
    Ann Surg Oncol; 2014 Apr; 21(4):1130-7. PubMed ID: 24370903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy.
    Hofmann G; Balic M; Dandachi N; Resel M; Schippinger W; Regitnig P; Samonigg H; Bauernhofer T
    Clin Biochem; 2013 Oct; 46(15):1585-9. PubMed ID: 23792261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer.
    Murakami S; Satomi A; Ishida K; Murai H; Matsuki M; Hashimoto T
    Cancer; 1994 Nov; 74(10):2745-8. PubMed ID: 7525035
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pepsinogen-II 100 bp ins/del gene polymorphism and its elevated circulating levels are associated with gastric cancer, particularly with Helicobacter pylori infection and intestinal metaplasia.
    Kumar S; Kumari N; Mittal RD; Ghoshal UC
    Gastric Cancer; 2016 Jul; 19(3):808-16. PubMed ID: 26486507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical significance of altering epithelial-mesenchymal transition in metastatic lymph nodes of gastric cancer.
    Okubo K; Uenosono Y; Arigami T; Yanagita S; Matsushita D; Kijima T; Amatatsu M; Uchikado Y; Kijima Y; Maemura K; Natsugoe S
    Gastric Cancer; 2017 Sep; 20(5):802-810. PubMed ID: 28247164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of mucins and E-cadherin in gastric carcinoma and their clinical significance.
    Zhang HK; Zhang QM; Zhao TH; Li YY; Yi YF
    World J Gastroenterol; 2004 Oct; 10(20):3044-7. PubMed ID: 15378790
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of
    Pandey I; Misra V; Pandey AT; Verma A
    Indian J Pathol Microbiol; 2022; 65(1):35-41. PubMed ID: 35074963
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Plasma E-cadherin levels in urinary bladder cancer: does it improve risk stratification?].
    Szarvas T; Hoffmann F; Becker M; Schenck M; Vom Dorp F; Rübben H; Jäger T
    Urologe A; 2011 Jan; 50(1):64-70. PubMed ID: 21153394
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationships of MMP-9, E-cadherin, and VEGF expression with clinicopathological features and response to chemosensitivity in gastric cancer.
    Gao H; Lan X; Li S; Xue Y
    Tumour Biol; 2017 May; 39(5):1010428317698368. PubMed ID: 28459196
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic significance of E-cadherin/catenin complex expression in gastric cancer.
    Joo YE; Park CS; Kim HS; Choi SK; Rew JS; Kim SJ
    J Korean Med Sci; 2000 Dec; 15(6):655-66. PubMed ID: 11194192
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of a cytoskeleton-associated kinase PEAK1 and E-cadherin in gastric cancer.
    Guo Q; Qin W; Li B; Yang H; Guan J; Liu Z; Li S
    Pathol Res Pract; 2014 Dec; 210(12):793-8. PubMed ID: 25445115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. E-cadherin and adenomatous polyposis coli mutations are synergistic in intestinal tumor initiation in mice.
    Smits R; Ruiz P; Diaz-Cano S; Luz A; Jagmohan-Changur S; Breukel C; Birchmeier C; Birchmeier W; Fodde R
    Gastroenterology; 2000 Oct; 119(4):1045-53. PubMed ID: 11040191
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Salivary and serum levels of soluble E-cadherin in patients with gastrointestinal cancers: A comparative study.
    Aznab M; Shahhosseini R; Safaei M; Mozaffari HR
    J Cancer Res Ther; 2023 Oct; 19(7):1982-1987. PubMed ID: 38376307
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The metastatic pattern of intestinal and diffuse type gastric carcinoma - A Dutch national cohort study.
    Koemans WJ; Luijten JCHBM; van der Kaaij RT; Grootscholten C; Snaebjornsson P; Verhoeven RHA; van Sandick JW
    Cancer Epidemiol; 2020 Dec; 69():101846. PubMed ID: 33126042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer.
    Ascaño JJ; Frierson H; Moskaluk CA; Harper JC; Roviello F; Jackson CE; El-Rifai W; Vindigni C; Tosi P; Powell SM
    Mod Pathol; 2001 Oct; 14(10):942-9. PubMed ID: 11598162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of an AlphaLISA assay to quantify serum core-fucosylated E-cadherin as a metastatic lung adenocarcinoma biomarker.
    Wen CL; Chen KY; Chen CT; Chuang JG; Yang PC; Chow LP
    J Proteomics; 2012 Jul; 75(13):3963-76. PubMed ID: 22634079
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer.
    Takahashi N; Iwasa S; Sasaki Y; Shoji H; Honma Y; Takashima A; Okita NT; Kato K; Hamaguchi T; Yamada Y
    J Cancer Res Clin Oncol; 2016 Aug; 142(8):1727-38. PubMed ID: 27256004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.